Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?

Mesoblast recently announced that the US FDA has granted Investigational New Drug clearance to move directly into a registrational clinical trial of Ryoncil in children with Duchenne muscular dystrophy, enrolling 76 patients aged 5 to 9 with time-to-stand at nine months as the primary endpoint. This trial positions Mesoblast to apply its first-in-class mesenchymal stromal cell therapy, already approved for pediatric steroid-refractory acute graft-versus-host disease, to a new high-need neuromuscular indication using an established manufacturing and safety platform. We’ll now examine how this FDA-cleared registrational DMD trial, built on Ryoncil’s existing pediatric use, may influence Mesoblast’s investment narrative.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Mesoblast Investment Narrative Recap

The core Mesoblast thesis is about turning first in class cell therapies into a scalable, multi indication business, with Ryoncil’s commercial rollout and late stage pipeline doing the heavy lifting. The new DMD registrational trial is an early stage, longer dated opportunity, so it does not materially change the near term focus on execution in pediatric SR aGvHD and progress in adult GvHD and chronic low back pain, or the key risk around cash burn if uptake lags.

Among recent announcements, the update that Ryoncil net sales reached US$30.3 million for the quarter, with launch revenue approaching US$100 million in the first year, feels most relevant. It shows how existing pediatric SR aGvHD use is starting to support the balance sheet just as Mesoblast layers on label extension shots like adult GvHD and now DMD, which together frame the main catalysts around broadening the Ryoncil franchise.

Yet this more exciting optionality also sits alongside the risk that ongoing operating cash outflows could force financing that existing shareholders should be aware of...

Read the full narrative on Mesoblast (it's free!)

Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from $-102.1 million today.

Uncover how Mesoblast's forecasts yield a A$3.83 fair value, a 90% upside to its current price.

Exploring Other PerspectivesASX:MSB 1-Year Stock Price Chart

Compared with consensus, the most cautious analysts were already modeling around US$275.4 million of revenue and US$48.0 million of earnings by 2029, so you should recognize that their much tougher stance on trial and adoption risk could shift again after an FDA cleared DMD registrational study like this.

Story Continues

Explore 12 other fair value estimates on Mesoblast - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Mesoblast research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Mesoblast research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

Outshine the giants: these 20 early-stage AI stocks could fund your retirement. AI is about to change healthcare. These 10 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Find 7 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MSB.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments